Lotus Eye Hospital and Institute Limited concluded its 29th Annual General Meeting on September 23, 2026. The meeting was conducted through Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with regulatory guidelines.

Meeting proceedings

The meeting commenced at 4:00 pm and concluded at 4:25 pm. Dr. Kavetha Sundaramoorthy, Chairperson, presided over the session. All directors of the company attended the meeting. The requisite quorum was present, allowing the Chairperson to call the meeting to order.

The Managing Director briefed shareholders on the services provided by the company and other significant aspects of its business operations. Subsequently, the Chief Financial Officer presented the financial highlights for the financial year 2025-26 (FY26).

Governance and audit status

Key governance updates included:

• The Statutory Auditors issued an unmodified audit report for FY26.
• Qualifications contained in the Secretarial Audit Report were duly addressed by the Management.
• Appropriate responses to these qualifications were provided in the Board's Report.
• The items of business contained in the AGM Notice were taken as read with shareholder permission.

Shareholder engagement

Shareholders were given an opportunity to speak and raise queries during the meeting. Out of three shareholders who registered to speak, only one was present. The questions raised by this shareholder were duly addressed by the Chief Financial Officer.

Following the conclusion of the discussion, the e-voting facility remained open for a further period of 30 minutes for shareholders who had not cast their votes earlier. The Chairperson thanked all shareholders for their participation before declaring the meeting closed.

Lotus Eye Hospital has scheduled its 29th Annual General Meeting for September 23, 2026, to approve a significant increase in the Managing Director’s remuneration and the reappointment of a retiring director. The meeting will be conducted via video conferencing.

Shareholders will consider an ordinary resolution to raise Ms. Sangeetha Sundaramoorthy’s monthly salary from ₹3,50,000 to ₹6,00,000, effective August 10, 2026. This revision applies to her remaining tenure until August 14, 2028. The Board cited her contribution to growth and expansion plans as justification for the hike.

Governance Changes

The agenda also includes the reappointment of Dr. Kavetha Sundaramoorthy, who retires by rotation. Additionally, shareholders must pass a special resolution to continue paying Dr. Kuttapalayam Songappan Ramalingam a monthly remuneration of ₹1,00,000 for FY27. This approval is required under SEBI LODR regulations because his annual pay exceeds 50% of the total remuneration for all non-executive directors.

Financial Context

The company reported a turnover of ₹5,489.03 lakh and a profit after tax of ₹8.04 lakh for FY26. Revenue from operations grew 8.4% year-on-year to ₹5,371.41 lakh from ₹4,956.25 lakh in FY25. However, net profit declined sharply from ₹73.93 lakh in the previous year due to initial costs associated with new center investments, including a facility in Gobichettipalayam. Management expects these investments to improve margins in the long run.

What the Numbers Show

The proposed remuneration revision represents a 71% increase in the Managing Director’s monthly fixed emoluments. With the company reporting a PAT of just ₹8.04 lakh against a turnover of ₹5,489.03 lakh in FY26, the annualized cost of this hike (₹30 lakh per year) is substantial relative to current profitability levels. Furthermore, the company’s total borrowings increased significantly to ₹1,142.97 lakh from nil in the prior year, reflecting debt-funded expansion.

Voting Details

Remote e-voting will be available from September 20 to September 22, 2026. The record date for determining voting eligibility is September 16, 2026. Shareholders holding shares as on this date may cast votes electronically through CDSL.